Acute megakaryoblastic leukaemia (AMKL) in children

A comparison of AMKL with and without Down syndrome

Asahito Hama, Hiroshi Yagasaki, Yoshiyuki Takahashi, Nobuhiro Nishio, Hideki Muramatsu, Nao Yoshida, Makito Tanaka, Hirokazu Hidaka, Nobuhiro Watanabe, Ayami Yoshimi, Kimikazu Matsumoto, Kazuko Kudo, Koji Kato, Keizo Horibe, Seiji Kojima

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

To characterize childhood acute megakaryoblastic leukaemia (AMKL), we reviewed 45 children with AMKL diagnosed between 1986 and 2005 at Nagoya University Hospital and Japanese Red Cross Nagoya First Hospital. Twenty-four patients (53%) had AMKL associated with Down syndrome (DS-AMKL) and 21 (47%) had non-DS-AMKL. The median age of the DS-AMKL patients was 21 months (range, 8-38 months) and that of non-DS-AMKL patients was 15 months (range, 2-185 months). The morphology of blast cells was categorized into three groups according to the stage of megakaryocyte maturation. The blast cells were more immature in DS-AMKL than in non-DS-AMKL in terms of morphology and immunophenotyping. Cytogenetic abnormalities of leukaemic cells were classified into seven categories: normal karyotype including constitutional trisomy 21 in DS-AMKL; numerical abnormalities only; t(1;22)(p13;q13); 3q21q26 abnormalities; t(16;21)(p11;q22); -5/del(5q) and/or -7/del(7q); and other structural changes. The outcome of children with either DS-AMKL or non-DS-AMKL is excellent. The 10-year overall survival estimate was 79% [95% confidence interval (CI): 54-90] for DS-AMKL and 76% (95% CI: 58-91) for non-DS-AMKL (P = 0.81) with a median follow-up of 78 months (range, 20-243 months). Our study shows the diverse heterogeneity of childhood AMKL and the need for subclassification according to cytogenetic and morphological features.

Original languageEnglish
Pages (from-to)552-561
Number of pages10
JournalBritish Journal of Haematology
Volume140
Issue number5
DOIs
Publication statusPublished - Mar 1 2008

Fingerprint

Leukemia, Megakaryoblastic, Acute
Down Syndrome
Confidence Intervals
Red Cross
Immunophenotyping
Megakaryocytes

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Hama, A., Yagasaki, H., Takahashi, Y., Nishio, N., Muramatsu, H., Yoshida, N., ... Kojima, S. (2008). Acute megakaryoblastic leukaemia (AMKL) in children: A comparison of AMKL with and without Down syndrome. British Journal of Haematology, 140(5), 552-561. https://doi.org/10.1111/j.1365-2141.2007.06971.x

Acute megakaryoblastic leukaemia (AMKL) in children : A comparison of AMKL with and without Down syndrome. / Hama, Asahito; Yagasaki, Hiroshi; Takahashi, Yoshiyuki; Nishio, Nobuhiro; Muramatsu, Hideki; Yoshida, Nao; Tanaka, Makito; Hidaka, Hirokazu; Watanabe, Nobuhiro; Yoshimi, Ayami; Matsumoto, Kimikazu; Kudo, Kazuko; Kato, Koji; Horibe, Keizo; Kojima, Seiji.

In: British Journal of Haematology, Vol. 140, No. 5, 01.03.2008, p. 552-561.

Research output: Contribution to journalArticle

Hama, A, Yagasaki, H, Takahashi, Y, Nishio, N, Muramatsu, H, Yoshida, N, Tanaka, M, Hidaka, H, Watanabe, N, Yoshimi, A, Matsumoto, K, Kudo, K, Kato, K, Horibe, K & Kojima, S 2008, 'Acute megakaryoblastic leukaemia (AMKL) in children: A comparison of AMKL with and without Down syndrome', British Journal of Haematology, vol. 140, no. 5, pp. 552-561. https://doi.org/10.1111/j.1365-2141.2007.06971.x
Hama, Asahito ; Yagasaki, Hiroshi ; Takahashi, Yoshiyuki ; Nishio, Nobuhiro ; Muramatsu, Hideki ; Yoshida, Nao ; Tanaka, Makito ; Hidaka, Hirokazu ; Watanabe, Nobuhiro ; Yoshimi, Ayami ; Matsumoto, Kimikazu ; Kudo, Kazuko ; Kato, Koji ; Horibe, Keizo ; Kojima, Seiji. / Acute megakaryoblastic leukaemia (AMKL) in children : A comparison of AMKL with and without Down syndrome. In: British Journal of Haematology. 2008 ; Vol. 140, No. 5. pp. 552-561.
@article{ae0045e9c68440cc92788a1ccc34a41f,
title = "Acute megakaryoblastic leukaemia (AMKL) in children: A comparison of AMKL with and without Down syndrome",
abstract = "To characterize childhood acute megakaryoblastic leukaemia (AMKL), we reviewed 45 children with AMKL diagnosed between 1986 and 2005 at Nagoya University Hospital and Japanese Red Cross Nagoya First Hospital. Twenty-four patients (53{\%}) had AMKL associated with Down syndrome (DS-AMKL) and 21 (47{\%}) had non-DS-AMKL. The median age of the DS-AMKL patients was 21 months (range, 8-38 months) and that of non-DS-AMKL patients was 15 months (range, 2-185 months). The morphology of blast cells was categorized into three groups according to the stage of megakaryocyte maturation. The blast cells were more immature in DS-AMKL than in non-DS-AMKL in terms of morphology and immunophenotyping. Cytogenetic abnormalities of leukaemic cells were classified into seven categories: normal karyotype including constitutional trisomy 21 in DS-AMKL; numerical abnormalities only; t(1;22)(p13;q13); 3q21q26 abnormalities; t(16;21)(p11;q22); -5/del(5q) and/or -7/del(7q); and other structural changes. The outcome of children with either DS-AMKL or non-DS-AMKL is excellent. The 10-year overall survival estimate was 79{\%} [95{\%} confidence interval (CI): 54-90] for DS-AMKL and 76{\%} (95{\%} CI: 58-91) for non-DS-AMKL (P = 0.81) with a median follow-up of 78 months (range, 20-243 months). Our study shows the diverse heterogeneity of childhood AMKL and the need for subclassification according to cytogenetic and morphological features.",
author = "Asahito Hama and Hiroshi Yagasaki and Yoshiyuki Takahashi and Nobuhiro Nishio and Hideki Muramatsu and Nao Yoshida and Makito Tanaka and Hirokazu Hidaka and Nobuhiro Watanabe and Ayami Yoshimi and Kimikazu Matsumoto and Kazuko Kudo and Koji Kato and Keizo Horibe and Seiji Kojima",
year = "2008",
month = "3",
day = "1",
doi = "10.1111/j.1365-2141.2007.06971.x",
language = "English",
volume = "140",
pages = "552--561",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Acute megakaryoblastic leukaemia (AMKL) in children

T2 - A comparison of AMKL with and without Down syndrome

AU - Hama, Asahito

AU - Yagasaki, Hiroshi

AU - Takahashi, Yoshiyuki

AU - Nishio, Nobuhiro

AU - Muramatsu, Hideki

AU - Yoshida, Nao

AU - Tanaka, Makito

AU - Hidaka, Hirokazu

AU - Watanabe, Nobuhiro

AU - Yoshimi, Ayami

AU - Matsumoto, Kimikazu

AU - Kudo, Kazuko

AU - Kato, Koji

AU - Horibe, Keizo

AU - Kojima, Seiji

PY - 2008/3/1

Y1 - 2008/3/1

N2 - To characterize childhood acute megakaryoblastic leukaemia (AMKL), we reviewed 45 children with AMKL diagnosed between 1986 and 2005 at Nagoya University Hospital and Japanese Red Cross Nagoya First Hospital. Twenty-four patients (53%) had AMKL associated with Down syndrome (DS-AMKL) and 21 (47%) had non-DS-AMKL. The median age of the DS-AMKL patients was 21 months (range, 8-38 months) and that of non-DS-AMKL patients was 15 months (range, 2-185 months). The morphology of blast cells was categorized into three groups according to the stage of megakaryocyte maturation. The blast cells were more immature in DS-AMKL than in non-DS-AMKL in terms of morphology and immunophenotyping. Cytogenetic abnormalities of leukaemic cells were classified into seven categories: normal karyotype including constitutional trisomy 21 in DS-AMKL; numerical abnormalities only; t(1;22)(p13;q13); 3q21q26 abnormalities; t(16;21)(p11;q22); -5/del(5q) and/or -7/del(7q); and other structural changes. The outcome of children with either DS-AMKL or non-DS-AMKL is excellent. The 10-year overall survival estimate was 79% [95% confidence interval (CI): 54-90] for DS-AMKL and 76% (95% CI: 58-91) for non-DS-AMKL (P = 0.81) with a median follow-up of 78 months (range, 20-243 months). Our study shows the diverse heterogeneity of childhood AMKL and the need for subclassification according to cytogenetic and morphological features.

AB - To characterize childhood acute megakaryoblastic leukaemia (AMKL), we reviewed 45 children with AMKL diagnosed between 1986 and 2005 at Nagoya University Hospital and Japanese Red Cross Nagoya First Hospital. Twenty-four patients (53%) had AMKL associated with Down syndrome (DS-AMKL) and 21 (47%) had non-DS-AMKL. The median age of the DS-AMKL patients was 21 months (range, 8-38 months) and that of non-DS-AMKL patients was 15 months (range, 2-185 months). The morphology of blast cells was categorized into three groups according to the stage of megakaryocyte maturation. The blast cells were more immature in DS-AMKL than in non-DS-AMKL in terms of morphology and immunophenotyping. Cytogenetic abnormalities of leukaemic cells were classified into seven categories: normal karyotype including constitutional trisomy 21 in DS-AMKL; numerical abnormalities only; t(1;22)(p13;q13); 3q21q26 abnormalities; t(16;21)(p11;q22); -5/del(5q) and/or -7/del(7q); and other structural changes. The outcome of children with either DS-AMKL or non-DS-AMKL is excellent. The 10-year overall survival estimate was 79% [95% confidence interval (CI): 54-90] for DS-AMKL and 76% (95% CI: 58-91) for non-DS-AMKL (P = 0.81) with a median follow-up of 78 months (range, 20-243 months). Our study shows the diverse heterogeneity of childhood AMKL and the need for subclassification according to cytogenetic and morphological features.

UR - http://www.scopus.com/inward/record.url?scp=38949211469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949211469&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06971.x

DO - 10.1111/j.1365-2141.2007.06971.x

M3 - Article

VL - 140

SP - 552

EP - 561

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -